reported that they modified and used the promoter of cholecystokinin type A receptor (CCKAR), which possessed relatively high activity in pancreatic cancer cells as compared with normal cells, to drive BikDD expression in a nude mouse xenograft mode of pancreatic cancer. Here, CCKAR is linked to pancreatic neoplasm.